Health
US-China Biotech Deal Scrutiny Proposed
The U.S. is set to propose a rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny.
Coverage timeline — 1 article
STAT News
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
2026-10-22 13:42 UTC